Biotechnology
Filter News
Found 46,680 articles
-
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
9/12/2018
Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
-
Bristol-Myers Squibb Announces Dividend Payable on November 1, 2018
9/12/2018
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of forty cents ($0.40) per share on the $.10 par value Common Stock of the corporation.
-
Celldom Awarded Phase II SBIR Grant to Advance Next Generation, High Throughput Single Cell Analysis Platform
9/12/2018
System integrates phenotypic and genomic information at massive scale to define heterogeneity in cell populations, accelerate research, drug discovery and drug development
-
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
9/12/2018
* FDA also recently approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Newron Pharmaceuticals to Host 2018 R&D Day on October 31 in New York City – Save the Date
9/12/2018
Newron Pharmaceuticals S.p.A. today announced that its 2018 R&D Day will be held in New York City on October 31, 2018, from 10:00AM to 1:00PM EDT.
-
SiteOne Therapeutics Appoints Scott Braunstein, MD to Board of Directors
9/12/2018
SiteOne Therapeutics today announced that Scott Braunstein, MD has been appointed to the Company's Board of Directors.
-
Boehringer Ingelheim To Donate 75,000 Doses Of Rabies Vaccine To The Global Alliance For Rabies Control Through Shots For Good Initiative
9/12/2018
In recognition of World Rabies Day on September 28, this significant rabies vaccine donation will support GARC's efforts to address deaths due to rabies in Madagascar.
-
Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
9/12/2018
Spectrum’s Phase 2 non-small cell lung cancer (NSCLC) study expanded to include two new cohorts for first-line NSCLC patients with EGFR or HER2 exon 20 insertion mutations
-
Visbiome® Vet probiotic to be the subject of two new clinical trials in domestic dogs
9/12/2018
ExeGi Pharma is pleased to announce two new clinical partnerships with the College of Veterinary Medicine at the University of Georgia and the University of Tennessee to study the Visbiome Vet probiotic in domestic dogs.
-
MRM Proteomics Inc and Exactis Innovation Partner to Establish Unique Clinical Proteomics Tools for Precision Medicine
9/12/2018
MRM Proteomics is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments.
-
Biocom Endorses Nathan Fletcher for San Diego County 4th District Supervisorial Seat
9/12/2018
Biocom, the association representing the California life science industry, today announced the endorsement of Nathan Fletcher for the San Diego County Board of Supervisors District 4 seat.
-
Wize Pharma Appoints Ellen Lubman to its Advisory Board
9/12/2018
Wize Pharma. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced the appointment of Ellen A. Lubman to its Advisory Board.
-
Welltok Acquires Leading Interactive Messaging Company Wellpass
9/12/2018
Welltok, a data-driven, enterprise SaaS company that delivers the industry's leading consumer health activation platform, today announced the acquisition of Wellpass, formerly Voxiva.
-
Abeona Therapeutics Announces Authorization to Commence Phase 1/2 Gene Therapy Clinical Study for Patients with MPS IIIB in Spain
9/12/2018
Abeona Therapeutics Inc. today announced authorization to move forward with a Phase 1/2 clinical trial in Spain for the Company’s gene therapy product ABO-101 (AAV-NAGLU) for patients with MPS IIIB (Sanfilippo syndrome type B).
-
FDA to Review Supplemental Biologics License Application for Praluent® (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
9/12/2018
Last month, FDA also approved Praluent label update for some patients currently requiring LDL apheresis therapy
-
Targovax Announces Publication of New Oncolytic Virus Data in the Journal of Medical Virology and Cancer Gene Therapy
9/12/2018
Validation of ONCOS-102 potential to generate tumor-specific immune responses in vivo
-
U.S. Department of Defense Awards $3.3 Million Grant to Alivio Therapeutics
9/12/2018
Research award will support preclinical activities to advance product candidate for the treatment of interstitial cystitis/bladder pain syndrome into the clinic
-
ImCheck Therapeutics Appoints Prof. René Hoet, PhD, as Chief Scientific Officer
9/12/2018
René Hoet brings over 20 years of experience as a leader in antibody discovery and development
-
Biopharma Company Arecor raises £6m for revolutionary diabetes treatments
9/12/2018
Arecor has raised £6 million from new and existing investors to develop groundbreaking pharmaceutical drugs to transform the treatment of diabetes.
-
Bristol-Myers Squibb’s Novel, Oral, Selective TYK2 Inhibitor Delivered Significant Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis in Phase 2 Trial
9/12/2018
Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index (PASI 75, PASI 90) were achieved following 12 weeks of treatment with ≥3 mg daily of BMS-986165